Daniel Glinatsi1,2, Paul Bird3,4, Frédérique Gandjbakhch3,4, Espen A Haavardsholm3,4, Charles G Peterfy3,4, Edward M Vital3,4, Paul Emery3,4, Philip G Conaghan3,4, Mikkel Østergaard3,4. 1. From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. daniel.glinatsi@gmail.com. 2. D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. daniel.glinatsi@gmail.com. 3. From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. 4. D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen.
Abstract
OBJECTIVE: To develop and validate a magnetic resonance imaging (MRI) tenosynovitis (TS) score for tendons at the wrist and metacarpophalangeal (MCP) joint levels in patients with rheumatoid arthritis (RA). METHODS: Axial T1-weighted precontrast and postcontrast fat-saturated MR image sets of the hands of 43 patients with RA initiating rituximab therapy were obtained at baseline and after 14, 26, 38, or 52 weeks. The MR images were scored twice by 4 readers. Nine tendon compartments of the wrist and 4 flexor tendon compartments at the MCP joints were assessed. Tenosynovitis was scored as follows: 0: No; 1: < 1.5 mm; 2: ≥ 1.5 mm but < 3 mm; 3: ≥ 3 mm peritendinous effusion and/or postcontrast enhancement. Intrareader and interreader intraclass correlation coefficients (ICC), smallest detectable change (SDC), percentage of exact and close agreement (PEA/PCA), and standardized response mean (SRM) were calculated. RESULTS: Intrareader and interreader ICC for status and change scores were very good (≥ 0.80) for total scores for all readers. Intrareader SDC was ≤ 3.0 and interreader SDC was < 2.0. The overall PEA/PCA intrareader and interreader agreements for change scores in all tendons were 73.8%/97.6% and 47.9%/85.0%, respectively. Average SRM was moderate for total scores and 60.5% of the patients had a tenosynovitis change score ≥ SDC. CONCLUSION: The TS score showed high intrareader and interreader agreement for wrist and finger tendons, with moderate responsiveness, and the majority of the patients showed a change above the SDC. This scoring system may be included as a component of the RAMRIS.
OBJECTIVE: To develop and validate a magnetic resonance imaging (MRI) tenosynovitis (TS) score for tendons at the wrist and metacarpophalangeal (MCP) joint levels in patients with rheumatoid arthritis (RA). METHODS: Axial T1-weighted precontrast and postcontrast fat-saturated MR image sets of the hands of 43 patients with RA initiating rituximab therapy were obtained at baseline and after 14, 26, 38, or 52 weeks. The MR images were scored twice by 4 readers. Nine tendon compartments of the wrist and 4 flexor tendon compartments at the MCP joints were assessed. Tenosynovitis was scored as follows: 0: No; 1: < 1.5 mm; 2: ≥ 1.5 mm but < 3 mm; 3: ≥ 3 mm peritendinous effusion and/or postcontrast enhancement. Intrareader and interreader intraclass correlation coefficients (ICC), smallest detectable change (SDC), percentage of exact and close agreement (PEA/PCA), and standardized response mean (SRM) were calculated. RESULTS: Intrareader and interreader ICC for status and change scores were very good (≥ 0.80) for total scores for all readers. Intrareader SDC was ≤ 3.0 and interreader SDC was < 2.0. The overall PEA/PCA intrareader and interreader agreements for change scores in all tendons were 73.8%/97.6% and 47.9%/85.0%, respectively. Average SRM was moderate for total scores and 60.5% of the patients had a tenosynovitis change score ≥ SDC. CONCLUSION: The TS score showed high intrareader and interreader agreement for wrist and finger tendons, with moderate responsiveness, and the majority of the patients showed a change above the SDC. This scoring system may be included as a component of the RAMRIS.
Entities:
Keywords:
MAGNETIC RESONANCE IMAGING; OMERACT; RHEUMATOID ARTHRITIS; TENOSYNOVITIS
Authors: Signe Møller-Bisgaard; Kim Hørslev-Petersen; Bo Ejbjerg; Merete Lund Hetland; Lykke Midtbøll Ørnbjerg; Daniel Glinatsi; Jakob Møller; Mikael Boesen; Robin Christensen; Kristian Stengaard-Pedersen; Ole Rintek Madsen; Bente Jensen; Jan Alexander Villadsen; Ellen-Margrethe Hauge; Philip Bennett; Oliver Hendricks; Karsten Asmussen; Marcin Kowalski; Hanne Lindegaard; Sabrina Mai Nielsen; Henning Bliddal; Niels Steen Krogh; Torkell Ellingsen; Agnete H Nielsen; Lone Balding; Anne Grethe Jurik; Henrik S Thomsen; Mikkel Østergaard Journal: JAMA Date: 2019-02-05 Impact factor: 56.272
Authors: Yousra J Dakkak; Xanthe M E Matthijssen; Désirée van der Heijde; Monique Reijnierse; Annette H M van der Helm-van Mil Journal: J Rheumatol Date: 2019-09-15 Impact factor: 4.666
Authors: Thomas Kirchgesner; Maria Stoenoiu; Patrick Durez; Nicolas Michoux; Bruno Vande Berg Journal: J Belg Soc Radiol Date: 2022-01-10 Impact factor: 1.894
Authors: D I Krijbolder; M Verstappen; F Wouters; L R Lard; Pdm de Buck; J J Veris-van Dieren; J L Bloem; M Reijnierse; Ahm van der Helm-van Mil Journal: Scand J Rheumatol Date: 2021-07-15 Impact factor: 3.057
Authors: Ying-Qian Mo; Ze-Hong Yang; Jun-Wei Wang; Qian-Hua Li; Xin-Yun Du; T W Huizinga; X M E Matthijssen; Guang-Zi Shi; Jun Shen; Lie Dai Journal: Arthritis Res Ther Date: 2019-12-11 Impact factor: 5.156